<DOC>
	<DOCNO>NCT01894451</DOCNO>
	<brief_summary>This research study pilot study , test ability investigational compound use human study . `` Investigational '' mean 89Zr-bevacizumab PET/CT imaging study . It also mean FDA ( U.S. Food Drug Administration ) approve 89Zr-bevacizumab PET/CT imaging use patient , include people type cancer . 89Zr-bevacizumab newly develop radiotracer . Radiotracers compound drug attach small amount radioactive substance . The amount compound drug radiotracer also small . Radiotracers use make image process happen body , affect body work . 89Zr-bevacizumab make drug bevacizumab radioactive substance zirconium-89 ( 89Zr ) . 89Zr-bevacizumab used imaging procedure call positron emission tomography/computed tomography ( PET/CT ) . This radiotracer use research study . Information research study suggest 89Zr-bevacizumab-PET/CT imaging may able measure new blood vessel formation determine cancer body cancer kill chemotherapy .</brief_summary>
	<brief_title>Pilot Study Zirconium-89 Bevacizumab Positron Emission Tomography Imaging Angiogenesis Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy</brief_title>
	<detailed_description>Many test procedure likely part regular cancer care may do even turn take part research study . If test procedure recently , may may repeat . - A medical history , include question health , current medication , allergy . This part regular cancer care . - Physical exam , doctor examine body , include measure height , weight , vital sign ( blood pressure , body temperature , pulse rate breathe rate ) . This part regular cancer care . - Blood test ( approximately 3 teaspoon ) drawn test check well organ function . This part regular cancer care . - Blood pregnancy test perform woman become pregnant . About 1 teaspoon blood drawn blood pregnancy test . This part regular cancer care . - Performance status , see carry daily activity . This do talk . This do part regular cancer care . If test show eligible participate research study , begin study treatment . If meet eligibility criterion , able participate research study . After screen procedure confirm eligible participate research study : Your primary oncologist decide chemotherapy receive . Before begin preoperative chemotherapy ( baseline ) : Before begin chemotherapy , undergo test procedure research study . Some test procedure part regular cancer care perform part research study . - FDG-PET/CT scan : Pictures organs take use PET ( Positron Emission Tomography ) scanner . At time , CT ( compute tomography ) scan perform . FDG , radioactive substance similar glucose ( sugar ) , inject vein use needle prior perform PET/CT scan . After injection , ask sit quietly one hour let FDG absorb body . After hour , ask lie flat back 50 minute PET CT image take . This FDG-PET/CT scan part regular cancer care . If test within 14 day study enrollment , may may test repeat . - MRI Scan : MRI ( Magnetic Resonance Imaging ) scan breast take . You receive injection dye MRI . You ask lie flat back scanner 30 minute picture take . This MRI scan part regular cancer care . If test within 14 day study enrollment , may may test repeat . - 89Zr-bevacizumab-PET/CT Scan : More picture organs take use PET ( Positron Emission Tomography ) scanner . At time , CT ( compute tomography ) scan perform . 89Zr-bevacizumab injected vein use needle . You observe approximately 1 hour injection 89Zr-bevacizumab . It take 3 4 day 89Zr-bevacizumab absorbed body . Therefore , research PET research CT scan ( 89Zr-bevacizumab-PET/CT ) perform 3 4 day 89Zr-bevacizumab injected vein . - This 89Zr-bevacizumab-PET/CT scan part research ( addition FDG-PET/CT scan ) part regular cancer care . - Vital sign , include heart rate , blood pressure , temperature , respiratory rate , perform immediately approximately 5 , 30 , 60 minute injection 89Zr-bevacizumab 89Zr-bevacizumab-PET/CT imaging . This part research . - Blood pregnancy test perform woman become pregnant . About 1 teaspoon blood drawn blood pregnancy test . If blood pregnancy test determine could study do longer 24 hour injection 89Zr-bevacizumab , repeat . - Blood test ( approximately 3 teaspoon ) drawn test check well organ function . This part regular cancer care . - Tumor biopsy : Prior start treatment , radiologist use breast MRI ultrasound image localize area tumor breast research biopsy . The biopsy procedure do outpatient set use do use needle obtain tissue . A local anesthetic give minimize pain ; however , procedure expect discomfort possible bruising . This biopsy part research . After 2 cycle preoperative chemotherapy : Two five day prior start third cycle chemotherapy , study test procedure perform . Some test procedure part regular cancer care perform part research study . - FDG-PET/CT scan : The procedure describe . This FDG-PET/CT scan part research . - MRI Scan : The procedure describe . This MRI scan part research . - 89Zr-bevacizumab-PET/CT Scan : The procedure describe . This 89Zr-bevacizumab-PET/CT scan part research . - Vital sign , include heart rate , blood pressure , temperature , respiratory rate , describe . This part research . - Blood pregnancy test perform woman become pregnant . This test described . This part research . - Blood test ( approximately 3 teaspoon ) drawn test check well organ function . This part regular cancer care . - Tumor biopsy : The procedure describe . This biopsy part research . After completion preoperative chemotherapy : Within 1-2 week complete preoperative chemotherapy , study test procedure repeat determine well cancer respond treatment . Some test procedure part regular cancer care perform part research study . - FDG-PET/CT scan : The procedure describe . This FDG-PET/CT scan part research . - MRI Scan : The procedure describe . This MRI scan part regular cancer care . - 89Zr-bevacizumab-PET/CT Scan : The procedure describe . This 89Zr-bevacizumab-PET/CT scan part research . - Vital sign , include heart rate , blood pressure , temperature , respiratory rate , describe . This part research . - Blood pregnancy test perform woman become pregnant . This test described . This part research . - Blood test ( approximately 3 teaspoon ) drawn test check well organ function . This part regular cancer care . Surgery : After complete preoperative chemotherapy , primary oncologist surgeon determine eligible undergo breast surgery . Breast surgery part regular cancer care . During surgery , tissue tumor remove test well cancer respond treatment . This part regular cancer care . If enough tissue available tissue test well tumor respond treatment , tissue take research . If able undergo breast surgery , tumor biopsy similar start 2 cycle chemotherapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Participants must meet follow criterion screen examination eligible participate study : Participants must histologically cytologically confirm HER2 negative invasive breast adenocarcinoma . Participants must clinical characteristic consistent IBC , characterize rapid onset clinical finding exemplify diffuse edema erythema breast , often without palpable mass . Age ≥ 21 year . Because dose adverse event data currently available use 89Zrbevacizumab participant &lt; 21 year age , child exclude study eligible future pediatric trial . Any stage eligible . Participants must eligible preoperative chemotherapy IBC determine treat physician . The effect 89Zrbevacizumab develop human fetus unknown . For reason radiopharmaceutical may teratogenic , woman childbearing potential men must agree use adequate contraception ( barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Ability willingness comply study procedure . Ability understand willingness sign write informed consent document . Participants must willing research biopsy baseline 2 cycle preoperative chemotherapy , possibly completion preoperative chemotherapy . ECOG performance status ≤ 2 . Participants exhibit follow condition screen eligible admission study : Pregnant woman exclude study 89Zrbevacizumab 18FFDG radiopharmaceutical potential teratogenic effect . Because radiation exposure nursing infant 89Zrbevacizumab 18FFDG , woman breastfeed also exclude study . In addition , bevacizumab may cause fetal harm base animal study ( 2 ) . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Major surgery significant bleeding episode within 28 day study initiation . Major surgery include : breast biopsy obtain diagnosis , placement radioopaque clip localize tumor tumor subsequent surgical resection , placement central venous access , pretreatment lymph node sample . Significant bleed episode define purpose study hemoptysis upper/lower gastrointestinal bleeding . Although bevacizumab administer tracer quantity study expect pharmacologic effect , participant major surgery significant bleeding episode within 28 day study initiation may higher risk bleed . Contraindications MRI contrast PET/CT include : Cardiac pacemaker , implanted cardiac defibrillator , pace wire , internal electrode Aneurysm clip Cochlear , otologic , ear implant Tissue expander SwanGanz Thermo Dilution Moderate renal insufficiency ( estimate GFR le 60 mL/min/1.73 m2 ) end stage renal disease ( estimate GFR le 15 mL/min/1.73 m2 serum creatinine 3 mg/dL ) , dialysis , patient renal failure chronic dialysis Severe claustrophobia History multiple severe allergic reaction attribute immunoglobulin MRI contrast agent . Any past current condition opinion study investigator would confound result study pose additional risk patient participation study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Inflammatory Breast Carcinoma</keyword>
	<keyword>89Zr-bevacizumab</keyword>
</DOC>